A woman who spent more than two decades tethered to a life-sustaining medical pump has been able to leave it behind after starting a new medication, marking what doctors call a major breakthrough for patients with a rare and serious lung condition.
Joyce Martin, 64, of Youngstown, Ohio, was diagnosed with Pulmonary Arterial Hypertension (PAH) in 2003 after initially being told she had asthma. The disease causes high blood pressure in the arteries of the lungs, leading to shortness of breath, fatigue, and eventually heart failure. For years, Martin relied on a continuous intravenous pump delivering medication through a catheter tunneled under her collarbone. The pump, which she carried in her purse, required daily maintenance and posed serious risks if interrupted. “You can’t go swimming when you’re connected to a pump,” said Dr. Kristin Highland, a pulmonologist at the Cleveland Clinic who has treated Martin since 2013.
Martin’s condition had deteriorated to the point where she was nearing a lung transplant. Then her doctor introduced her to Sotatercept, a new drug that targets the underlying mechanisms of PAH rather than just managing symptoms. Dr. Highland called it “probably the most significant advancement” she has seen for the disease. Martin responded so well to the treatment that she was able to stop using her IV pump entirely. “I really did think I was going to have that the rest of my life,” Martin said. “But you just choose joy every day.” Now she can do something as simple as wearing a dress again, something the pump had made difficult for years.
For the roughly 500 to 1,000 new cases of PAH diagnosed in the United States each year, Sotatercept offers a new horizon. While not a cure, the drug has allowed some patients to reduce or eliminate the need for continuous intravenous therapy, dramatically improving quality of life. Martin’s case is a hopeful example of how targeted medical advances can transform lives even after decades of struggle. Researchers continue to study the drug’s long-term effects, and doctors are optimistic that more patients will benefit from this shift in treatment strategy.